Early Cytokine Signatures of Hospitalized Mild and Severe COVID-19 Patients: A Prospective Observational Study

References

• Keam S, Megawati D, Patel SK, Tiwari R, Dhama K, Harapan H. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. Rev Med Virol. 2020;30(5):e2123. doi:10.1002/rmv.2123
   PubMed Web of Science ®Google Scholar
• Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi:10.3389/fimmu.2020.01446
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Intern J Infectious Dis. 2020:56.
   Web of Science ®Google Scholar
• Castillo-Olivares J, Wells DA, Ferrari M, et al. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. Front Immunol. 2021;12:748291. doi:10.3389/fimmu.2021.748291
   PubMed Web of Science ®Google Scholar
• Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–399. doi:10.1080/10408363.2020.1770685
   PubMed Web of Science ®Google Scholar
• Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine. 2021;137:155323. doi:10.1016/j.cyto.2020.155323
   PubMed Web of Science ®Google Scholar
• Dorgham K, Quentric P, Gökkaya M, et al. Distinct cytokine profiles associated with COVID-19 severity and mortality. J Allergy Clin Immunol. 2021;147(6):2098–2107. doi:10.1016/j.jaci.2021.03.047
   PubMedGoogle Scholar
• Lebedeva A, Molodtsov I, Anisimova A, et al. Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy. Int J Mol Sci. 2022;23(14):1–26. doi:10.3390/ijms23147937
   Web of Science ®Google Scholar
• Angioni R, Sánchez-Rodríguez R, Munari F, et al. Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients. Cell Death Dis. 2020;11(11):957. doi:10.1038/s41419-020-03151-z
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang M, Xin Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):1741. doi:10.1002/JLB.3COVR0520-272R
   Web of Science ®Google Scholar
• Saudi Center for Disease Prevention and Control. Coronavirus Disease COVID-19 Guidelines; 2020.
   Google Scholar
• National Institutes of Health. Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19). Nih. 2021;2019:1–243.
   Google Scholar
• Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: from clinical significance to quantification. Adv.Sci. 2021;8:2004433. doi:10.1002/advs.202004433
   Web of Science ®Google Scholar
• Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270–2279. doi:10.1093/eurheartj/ehaa1103
   PubMed Web of Science ®Google Scholar
• Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020;92(11):2409–2411. doi:10.1002/jmv.26097
   PubMed Web of Science ®Google Scholar
• Lu L, Zhang H, Dauphars DJ, He YW. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. Trends Immunol. 2021;42(1):3–5. doi:10.1016/j.it.2020.10.012
   PubMed Web of Science ®Google Scholar
• Aleanizy FS, Alqahtani FY, Alanazi MS, et al. Clinical characteristics and risk factors of patients with severe COVID-19 in Riyadh, Saudi Arabia: a retrospective study. J Infect Public Health. 2021;14(9):1133–1138. doi:10.1016/j.jiph.2021.07.014
   PubMed Web of Science ®Google Scholar
• Renu K, Subramaniam MD, Chakraborty R, et al. The role of Interleukin-4 in COVID-19 associated male infertility - A hypothesis. J Reprod Immunol. 2020;142:103213. doi:10.1016/j.jri.2020.103213
   PubMed Web of Science ®Google Scholar
• de Lang A, Osterhaus ADME, Haagmans BL. Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology. 2006;353(2):474–481. doi:10.1016/j.virol.2006.06.011
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153(1):13–19. doi:10.1093/jb/mvs136
   PubMed Web of Science ®Google Scholar
• Maloney JP, Gao L. Proinflammatory cytokines increase vascular endothelial growth factor expression in alveolar epithelial cells. Mediators Inflamm. 2015;2015:387842. doi:10.1155/2015/387842
   PubMed Web of Science ®Google Scholar
• Guerra-López JA, Amezcua-Castillo LM, González-Pacheco H, Amezcua-Guerra LM. Levels of Vascular Endothelial Growth Factor and Its Association with Pulmonary Embolism in COVID-19. J Interf Cytokine Res. 2022;42(8):444–448. doi:10.1089/jir.2022.0034
   PubMed Web of Science ®Google Scholar
• Shibuya M. VEGF-VEGFR Signals in Health and Disease. Biomol Ther (Seoul). 2014;22(1):1–9. doi:10.4062/biomolther.2013.113
   PubMed Web of Science ®Google Scholar
• Cao Y. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients. Exploration. 2021;1(2):20210051. doi:10.1002/EXP.20210051
   Google Scholar
• Solimando AG, Marziliano D, Ribatti D. SARS-CoV-2 and Endothelial Cells: vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows. Biomedicines. 2022;10(9). doi:10.3390/biomedicines10092242
   PubMed Web of Science ®Google Scholar
• Galbraith MD, Kinning KT, Sullivan KD, et al. Specialized interferon action in COVID-19. Proc Natl Acad Sci. 2022;119(11):e2116730119. doi:10.1073/pnas.2116730119
   PubMed Web of Science ®Google Scholar
• Gadotti AC, de Castro Deus M, Telles JP, et al. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171. doi:10.1016/j.virusres.2020.198171
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang J, Liu C, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97. doi:10.1186/s10020-020-00230-x
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Jøntvedt Jørgensen M, Holter JC, Christensen EE, et al. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. Sci Rep. 2020;10(1):1–11. doi:10.1038/s41598-020-78710-7
   PubMed Web of Science ®Google Scholar
• Kalinina O, Golovkin A, Zaikova E, et al. Cytokine Storm Signature in Patients with Moderate and Severe COVID-19. Int J Mol Sci. 2022;23(16). doi:10.3390/ijms23168879
   Web of Science ®Google Scholar
• Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. doi:10.1016/j.cytogfr.2020.06.001
   PubMed Web of Science ®Google Scholar
• Neumann J, Prezzemolo T, Vanderbeke L, et al. Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. Clin Transl Immunol. 2020;9(11):e1204. doi:10.1002/cti2.1204
   PubMed Web of Science ®Google Scholar
• Qi S, Ngwa C, Morales Scheihing DA, et al. Sex differences in the immune response to acute COVID-19 respiratory tract infection. Biol Sex Differ. 2021;12(1):66. doi:10.1186/s13293-021-00410-2
   PubMed Web of Science ®Google Scholar
• Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: focus on Severity and Mortality. Front Public Heal. 2020;8:152. doi:10.3389/fpubh.2020.00152
   PubMed Web of Science ®Google Scholar
• Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34(2):339–343. doi:10.23812/Editorial-Conti-3
   PubMed Web of Science ®Google Scholar